627 related articles for article (PubMed ID: 19818686)
1. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
2. Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)-Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study.
Grabar S; Hleyhel M; Belot A; Bouvier AM; Tattevin P; Pacanowski J; Genet P; Pradier C; Salmon D; Simon A; Pourcher V; Spano JP; Poizot-Martin I; Costagliola D
HIV Med; 2019 Mar; 20(3):222-229. PubMed ID: 30693646
[TBL] [Abstract][Full Text] [Related]
3. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.
Bruyand M; Thiébaut R; Lawson-Ayayi S; Joly P; Sasco AJ; Mercié P; Pellegrin JL; Neau D; Dabis F; Morlat P; Chêne G; Bonnet F;
Clin Infect Dis; 2009 Oct; 49(7):1109-16. PubMed ID: 19705973
[TBL] [Abstract][Full Text] [Related]
4. Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018.
Choufany M; Weiss L; Makinson A; Roul H; Livrozet JM; Pourcher V; Melica G; Rioux C; Viard JP; Marshall E; Grabar S; Costagliola D
Clin Infect Dis; 2023 Apr; 76(8):1364-1371. PubMed ID: 36527700
[TBL] [Abstract][Full Text] [Related]
5. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.
Hleyhel M; Hleyhel M; Bouvier AM; Belot A; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Spano JP; Costagliola D; Grabar S;
AIDS; 2014 Sep; 28(14):2109-18. PubMed ID: 25265077
[TBL] [Abstract][Full Text] [Related]
6. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
Lacombe JM; Boue F; Grabar S; Viget N; Gazaignes S; Lascaux-Cametz AS; Pacanowski J; Partisani M; Launay O; Matheron S; Rosenthal E; Rouveix E; Tattevin P; de Truchis P; Costagliola D; Goedert JJ
AIDS; 2013 Feb; 27(4):635-43. PubMed ID: 23196937
[TBL] [Abstract][Full Text] [Related]
7. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
[TBL] [Abstract][Full Text] [Related]
8. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
9. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
10. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort.
Hleyhel M; Belot A; Bouvier AM; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Costagliola D; Grabar S;
Clin Infect Dis; 2013 Dec; 57(11):1638-47. PubMed ID: 23899679
[TBL] [Abstract][Full Text] [Related]
11. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.
; Bohlius J; Schmidlin K; Costagliola D; Fätkenheuer G; May M; Caro-Murillo AM; Mocroft A; Bonnet F; Clifford G; Karafoulidou A; Miro JM; Lundgren J; Chene G; Egger M
Antivir Ther; 2009; 14(8):1065-74. PubMed ID: 20032536
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
[TBL] [Abstract][Full Text] [Related]
14. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
15. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
[TBL] [Abstract][Full Text] [Related]
17. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
18. Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ; Neuhaus J; Bower M; Gey D; Hatzakis A; Henry K; Hidalgo J; Lourtau L; Neaton JD; Tambussi G; Abrams DI
AIDS; 2007 Sep; 21(14):1957-63. PubMed ID: 17721103
[TBL] [Abstract][Full Text] [Related]
19. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort.
Hleyhel M; Belot A; Bouvier AM; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Spano JP; Costagliola D; Grabar S;
Int J Cancer; 2015 Nov; 137(10):2443-53. PubMed ID: 25976897
[TBL] [Abstract][Full Text] [Related]
20. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
